OBJECTIVE: To study the current situation and development trend of endocrine therapy drugs for breast cancer in 6 regions of China（ Beijing

Guangzhou

Hangzhou

Tianjin

Chengdu and Shanghai）. METHODS:The application of endocrine therapy drugs for breast cancer in the mentioned regions from 2011 to 2017 was statistically analyzed in terms of consumption sum

defined daily dose system（ DDDs）

defined daily cost（ DDC）growth. And the characteristics of drug-use and changes of endocrine therapy drugs for breast cancer were analyzed.RESULTS: From 2011 to 2017

the consumption sum of endocrine therapy drugs for breast cancer in the mentioned regions participating in this prescription analysis project increased from 11 915 300 yuan to 34 069 300 yuan

with an increase of 186%. Among all drugs

letrozole and anastrozole dominated the top two places ranked by cumsumption

while DDDs of letrozole

tamoxifen and anastrozole ranked in the top 3

and DDC of leuprorelin took the lead.CONCLUSIONS: Prescription quantity and consumption sum of endocrine therapy drugs for breast cancer in 6 regions of China are on the rise as a whole. In combination with relevant guidelines and requirements for disease treatment

clinicians should make comprehensive judgment after fully considering the safety

efficacy and economy of drugs when formulate rational treatment plans.